Skip to content
Screener

AbCellera Biologics Inc. ABCL Total Liabilities & Equity

Total Liabilities & Equity at other companies

Schrodinger logo
SchrodingerSDGR
$640.39M-7.0%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$676.21M+13.5%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$1.21B-6.9%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$990.05M-19.6%
Absci Corporation logo
Absci CorporationABSI
$195.59M-15.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$490.78M+288%

Other financials

Income statement

See full
Revenue$4.1M-76.3%
Operating income-$62.8M-26.6%
Net income-$55.4M-59.6%
EPS (diluted)-$0.18-50.0%

Balance sheet

See full
Cash & equivalents$145.1M+23.5%
Total debt$135.6M-4.5%
Total equity$896.0M-11.0%
Total assets$1.3B-6.7%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$2.1M-84.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.99B+62.2%
Enterprise value$1.98B+58.2%
P/S30.1×-7.3×

Profitability

See full
Operating margin-340.3%-127pp
Net margin-248.8%-83.6pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-17.3%+2.1pp
Debt / equity0.2×0.0×
Current ratio12.8×+1.7×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001703057-26-000046
Line itemDecember 31, 2025June 30, 2026
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2025 and June 30, 2026: 300,600,710 and 306,469,632 shares issued and outstanding at December 31, 2025 and June 30, 2026, respectively802,341821,242
Additional paid-in capital198,279206,004
Accumulated other comprehensive loss(4,234)(3,152)
Accumulated deficit(29,482)(128,074)
Total shareholders' equity966,904896,020
Total liabilities and shareholders' equity$1,356,950$1,307,575

Item 1. Financial Statements (Unaudited)

FAQ

What is AbCellera Biologics Inc.'s total liabilities & equity?
AbCellera Biologics Inc. (ABCL) reported total liabilities & equity of $1.31B in Q2 2026.
How has AbCellera Biologics Inc.'s total liabilities & equity changed year-over-year?
AbCellera Biologics Inc.'s total liabilities & equity decreased by 6.7% year-over-year, from $1.4B to $1.31B.
What is the long-term trend for AbCellera Biologics Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s total liabilities & equity has grown at a 6.2% compound annual growth rate (CAGR), from $1.01B to $1.36B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about AbCellera Biologics Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude